Caplin Point Laboratories Ltd stock PB Ratio (=5.48) is close to 1-year high of 5.48.
The historical rank and industry rank for Caplin Point Laboratories's PB Ratio or its related term are showing as below:
NSE:CAPLIPOINT'
s PB Ratio Range Over the Past 10 Years
Min: 2.3 Med: 4.63 Max: 19.96
Current: 5.48
During the past 13 years, Caplin Point Laboratories's highest PB Ratio was 19.96. The lowest was 2.30. And the median was 4.63.
NSE:CAPLIPOINT's PB Ratio is ranked worse than 84.11% of 925
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs NSE:CAPLIPOINT: 5.48
During the past 12 months, Caplin Point Laboratories's average Book Value Per Share Growth Rate was 25.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 24.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 24.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 37.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Caplin Point Laboratories was 67.00% per year. The lowest was 10.40% per year. And the median was 32.20% per year.
Back to Basics: PB Ratio
Caplin Point Laboratories (NSE:CAPLIPOINT) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Caplin Point Laboratories PB Ratio Related Terms
Caplin Point Laboratories PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caplin Point Laboratories PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Caplin Point Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Caplin Point Laboratories (NSE:CAPLIPOINT) has a PB Ratio of 5.48 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Caplin Point Laboratories and its competitors. This is 18% above median its historical median of 4.63. Over the past decade, Caplin Point Laboratories' PB Ratio has ranged from 2.30 to 19.96. According to the industry distribution chart, Caplin Point Laboratories ranks #778 out of 925 companies in the Drug Manufacturers industry, placing it in the top 84.1%.
Is Caplin Point Laboratories' PB Ratio too high?
Caplin Point Laboratories' current PB Ratio of 5.48 is 18% above median its 10-year median of 4.63. Over the past 10 years, this metric has ranged from a low of 2.30 to a high of 19.96. The Drug Manufacturers industry median PB Ratio is 1.91. Caplin Point Laboratories' value of 5.48 is 186.9% above this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #778 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Caplin Point Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #778 out of 925 companies for PB Ratio. This places Caplin Point Laboratories in the lower half of its industry. The industry median PB Ratio is 1.91. Caplin Point Laboratories' value of 5.48 is 186.9% above this benchmark. Historically, Caplin Point Laboratories' own PB Ratio has ranged from 2.30 to 19.96 over the past decade. While the company's 10-year median is 4.63 vs. the industry median of 1.91, Caplin Point Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current PB Ratio of 5.48 is 186.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Caplin Point Laboratories and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current PB Ratio is 5.48, which is 18% above median its own 10-year median of 4.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,085.60, compared to a current price of ₹2,583.60 — trading 23.9% above its estimated fair value. The current PB Ratio is 5.48, which is 18% above median its 10-year median of 4.63 and 186.9% above the Drug Manufacturers industry median of 1.91. Caplin Point Laboratories' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current PB Ratio is 5.48 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,583.60 is trading 23.9% above its estimated GF Value™ of ₹2,085.60.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
PB Ratio: 5.48 (18% above median its 10-year median of 4.63)
GF Value™: ₹2,085.60 vs. price of ₹2,583.60 (23.9% above fair value)
Industry Position: 186.9% above the Drug Manufacturers median (#778 of 925)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
90GF Score
Get the complete analysis for NSE:CAPLIPOINT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
